KR20090033886A - 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제 - Google Patents

안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제 Download PDF

Info

Publication number
KR20090033886A
KR20090033886A KR1020097002077A KR20097002077A KR20090033886A KR 20090033886 A KR20090033886 A KR 20090033886A KR 1020097002077 A KR1020097002077 A KR 1020097002077A KR 20097002077 A KR20097002077 A KR 20097002077A KR 20090033886 A KR20090033886 A KR 20090033886A
Authority
KR
South Korea
Prior art keywords
antagonist
alkyl
receptor
subject
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097002077A
Other languages
English (en)
Korean (ko)
Inventor
데브라 엘. 플리너
앨런 알. 쉐퍼드
이옥-호우 팽
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20090033886A publication Critical patent/KR20090033886A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097002077A 2006-07-25 2007-07-25 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제 Ceased KR20090033886A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
US60/833,080 2006-07-25

Publications (1)

Publication Number Publication Date
KR20090033886A true KR20090033886A (ko) 2009-04-06

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002077A Ceased KR20090033886A (ko) 2006-07-25 2007-07-25 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제

Country Status (11)

Country Link
US (2) US20080025973A1 (enExample)
EP (1) EP2068856A2 (enExample)
JP (1) JP2009544734A (enExample)
KR (1) KR20090033886A (enExample)
CN (1) CN101505744A (enExample)
AU (1) AU2007279311A1 (enExample)
BR (1) BRPI0714593A2 (enExample)
CA (1) CA2657480A1 (enExample)
MX (1) MX2009000907A (enExample)
WO (1) WO2008014338A2 (enExample)
ZA (1) ZA200900316B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
US20110009453A1 (en) * 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
WO2010129553A1 (en) * 2009-05-05 2010-11-11 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
RU2012105453A (ru) * 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
WO2011038446A1 (en) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Cosmetic foam
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제
EP1546110A4 (en) * 2002-07-30 2008-03-26 Univ Virginia COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
US20060173046A1 (en) * 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
US7888527B2 (en) * 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
EP1935874A4 (en) * 2005-10-12 2010-10-13 Toa Eiyo Ltd S1P3 RECEPTOR ANTAGONIST
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Also Published As

Publication number Publication date
ZA200900316B (en) 2010-05-26
JP2009544734A (ja) 2009-12-17
CA2657480A1 (en) 2008-01-31
US20080025973A1 (en) 2008-01-31
US20100183629A1 (en) 2010-07-22
WO2008014338A3 (en) 2008-12-24
CN101505744A (zh) 2009-08-12
MX2009000907A (es) 2009-02-04
EP2068856A2 (en) 2009-06-17
WO2008014338A2 (en) 2008-01-31
BRPI0714593A2 (pt) 2013-05-07
AU2007279311A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
KR20090033886A (ko) 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제
Tokushige et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
US10149884B2 (en) Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
MXPA06007062A (es) Antagonistas cdk2 como antagonistas del factor de transcripcion c-maf de forma corta para el tratamiento de glaucoma.
KR101103141B1 (ko) Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장치료제
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US20100247548A1 (en) Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
Zhan et al. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
KR20080111092A (ko) 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제
Virani et al. An Update on Pharmacotherapy of Glaucoma
LEINO et al. Recent developments in anti-glaucoma drug research
CN103402508A (zh) 芳基磺酰胺衍生物的剂量
WO2020166679A1 (ja) 眼圧下降用医薬組成物
Carvalho et al. Topical use of injectable dexmedetomidine in combination with dorzolamide for the intraocular pressure reduction in dogs: a preliminary study
CN112972472A (zh) 化合物a740003在制备治疗年龄相关性黄斑变性的药物中的应用
US20100158897A1 (en) Pai-1 modulators for the treatment of ocular disorders
JP2004189735A (ja) Ｌｉｍキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131025

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I